BE AGILE: No new safety signals in AS pts treated with BKZ ( IL-17F/IL-17Ai) and remains efficacious as a potential treatment in AS. Abs 0491 #ACR21 #RheumNow @RheumNow https://t.co/fGT8n5Hx9C https://t.co/rjPTla7JId
Links:
Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylit…
http://ow.ly/BsKQ50Gqj2R
06-11-2021
